Your session is about to expire
← Back to Search
Virus Therapy
PSMA-PET Guided Radiotherapy for Prostate Cancer (PSMA-PETgRT Trial)
Phase 2 & 3
Waitlist Available
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subjects with newly diagnosed high-risk (NCCN) localized prostate cancer and CAPRA score 6-10
ECOG 0-1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
PSMA-PETgRT Trial Summary
This trial is testing whether a new type of PET scan is better than the current standard of care for finding cancer metastases, which would then inform more effective radiation treatment.
Who is the study for?
This trial is for men with high-risk localized prostate cancer or those who've had treated prostate cancer but now have rising PSA levels. They should have a small number (≤5) of metastases, be in good physical condition (ECOG 0-1), and not have received certain prior treatments like recent androgen deprivation therapy.Check my eligibility
What is being tested?
The study compares two ways to plan radiotherapy: one uses a new type of PET/CT scan that's better at finding where the cancer has spread, while the other uses standard imaging. The goal is to see if using this new scan leads to better treatment outcomes.See study design
What are the potential side effects?
While the document doesn't specify side effects related to PSMA-PET/CT scans, generally, PET scans are considered safe. However, there may be risks associated with radiation exposure and allergic reactions to contrast agents used during imaging.
PSMA-PETgRT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have high-risk prostate cancer with a CAPRA score between 6-10.
Select...
I am fully active or can carry out light work.
Select...
I have prostate cancer and am scheduled for radiotherapy aimed at curing it.
Select...
I had prostate cancer treated but my PSA levels have since increased.
PSMA-PETgRT Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Failure-free survival
Secondary outcome measures
Acute and delayed toxicities
Detection yield of PSMA PET imaging
Health-related quality of life
+2 morePSMA-PETgRT Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: PSMA-PETgRTExperimental Treatment1 Intervention
PSMA-PET/CT imaging is performed during treatment planning. Treating physicians are informed of test results and advised to include up to 5 PSMA-PET avid sites distant to the prostate gland, if present, in the radiotherapy treatment plan.
Group II: StandardActive Control1 Intervention
Patient's receive standard care radiotherapy and do not undergo PSMA-PET/CT imaging.
Find a Location
Who is running the clinical trial?
Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
366 Previous Clinical Trials
129,507 Total Patients Enrolled
4 Trials studying Prostate Cancer
1,979 Patients Enrolled for Prostate Cancer
Progenics Pharmaceuticals, Inc.Industry Sponsor
33 Previous Clinical Trials
4,820 Total Patients Enrolled
17 Trials studying Prostate Cancer
2,204 Patients Enrolled for Prostate Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have 5 or fewer cancer spread areas, with specific rules for counting.I've had a bone scan and CT of my pelvis within the last 3 months.I have high-risk prostate cancer with a CAPRA score between 6-10.I am fully active or can carry out light work.I have prostate cancer and am scheduled for radiotherapy aimed at curing it.I have had or will have a PET scan.I stopped hormone therapy for cancer less than a year ago.I had prostate cancer treated but my PSA levels have since increased.
Research Study Groups:
This trial has the following groups:- Group 1: PSMA-PETgRT
- Group 2: Standard
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is recruitment still underway for this experiment?
"According to the website, this study is not currently looking for patients. The trial was posted on 5/15/2018 and updated last on 8/5/2022. There are 1359 other trials actively recruiting participants."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger